Alkermes’ investigational drug helped people with a type of narcolepsy stay awake during the day in a mid-stage trial.

Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Alkermes ALKS announced positive top-line data from the phase II Vibrance-1 study, which evaluated its novel, investigational ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

Topline data were announced from two phase 3 trials evaluating oveporexton in patients with narcolepsy type 1.

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts have guessed it could ultimately generate billions in sales.

Alkermes plc (NASDAQ:ALKS) on Monday released topline results from the randomized double-blind treatment period of the ...

If you're interested in driving something big with the smoothness of a CVT transmission, SUVs from these brands could be ...

Alkermes stock skidded Monday on the back of mixed results for its experimental narcolepsy treatment, an orexin agonist.

Alkermes plc (Nasdaq: ALKS) today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with ...

Key Points Shopify's moat and vast runway for growth make its prospects highly attractive. Axsome Therapeutics has a robust ...